NASDAQ$RLMD
Relmada Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Relmada Therapeutics, Inc. reported its Q1 2025 earnings with a net loss of $17.56 million and negative operating cash flows of $18.07 million.
Relmada Therapeutics, Inc. reported a net loss of $17.56 million for the three months ended March 31, 2025, with total operating expenses of $18.22 million. The company's cash and cash equivalents decreased significantly, raising substantial doubt about its ability to continue as a going concern.
- Net loss for Q1 2025 was $17.56 million, an improvement from $21.83 million in Q1 2024.
- Operating expenses decreased to $18.22 million in Q1 2025 from $22.99 million in Q1 2024, primarily due to winding down REL-1017 studies.
- The company reported negative cash flows from operations of $18.07 million for Q1 2025.
- Relmada acquired Sepranolone and in-licensed NDV-01, diversifying its pipeline and terminating the psilocybin program.
Headline financials
Revenue & EPS history
Relmada · Revenue · Quarterly
$0
Forward guidance
Relmada Therapeutics, Inc. is focused on advancing its NDV-01 and Sepranolone programs, with several key milestones anticipated over the next 12 months. The company acknowledges insufficient liquidity to sustain operations for one year and is evaluating financing strategies.
Tailwinds
- Anticipated NDV-01 Six-month data from ongoing Phase 2 NMBIC Study in Mid 2025.
- Expected NDV-01 Nine-month data from ongoing Phase 2 NMBIC Study in 3rd Quarter 2025.
- Projected NDV-01 Twelve-month data from ongoing Phase 2 NMBIC Study by Year end 2025.
- Anticipated NDV-01 United States Investigative New Drug clearance in 1st Half 2026.
- Planned initiation of Sepranolone clinical trial in PWS in 1st Half 2026.
Headwinds
- The company is projecting insufficient liquidity to sustain its operations through one year following the financial statements issuance date.
- There is substantial doubt about the company's ability to continue as a going concern.
- No assurances that additional financing will be secured or be sufficient to meet needs on favorable terms.
- The REL-1017 program has been paused pending comprehensive data review, with uncertainty regarding its future.
- The psilocybin development program has been terminated, ceasing all related obligations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2025
-1.6%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+3.2%
Avg return
30 days after
35%
15 / 43 earnings
Positive
+10.8%
Q4 2024
Best reaction
-29.0%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -2.0% | -12.5% | — | |
| Q1 2026 | +1.2% | -6.1% | -11.4% | |
| Q3 2025 | +1.8% | +7.7% | +4.6% | |
| Q2 2025 | -2.5% | -5.6% | +174.1% | |
| Q1 2025 | +6.6% | +33.4% | +53.6% | |
| Q4 2024 | +10.8% | -5.1% | +33.2% | |
| Q3 2024 | -3.5% | -2.9% | -86.5% | |
| Q2 2024 | -29.0% | -29.0% | -25.9% | |
| Q1 2024 | -0.5% | -7.6% | -22.8% | |
| Q4 2023 | -19.6% | -12.0% | -22.1% | |
| Q3 2023 | -2.0% | -7.5% | -16.1% | |
| Q2 2023 | +3.0% | +17.4% | +34.5% | |
| Q1 2023 | -9.2% | -10.7% | -19.0% | |
| Q4 2022 | -3.0% | +4.3% | +12.8% | |
| Q3 2022 | +10.4% | +2.3% | -53.5% | |
| Q2 2022 | -0.7% | -2.8% | +8.9% | |
| Q1 2022 | -12.4% | -18.5% | -20.1% | |
| Q4 2021 | +7.5% | +10.4% | +4.9% | |
| Q3 2021 | -8.2% | -12.0% | -24.4% | |
| Q2 2021 | +4.8% | +0.6% | +13.6% | |
| Q1 2021 | -4.1% | +0.0% | -10.9% | |
| Q4 2020 | -10.4% | -7.4% | +4.3% | |
| Q3 2020 | +0.0% | +8.3% | +0.9% | |
| Q2 2020 | -0.3% | +7.7% | +0.0% | |
| Q1 2020 | +9.6% | +8.5% | +12.6% | |
| Q4 2019 | -0.1% | -1.7% | +19.7% | |
| Q3 2019 | -3.0% | -5.1% | +29.9% | |
| Q2 2019 | -4.0% | -8.5% | +106.8% | |
| Q1 2019 | +0.0% | +1.7% | +13.9% | |
| Q3 2018 | +5.1% | +2.6% | -1.7% | |
| Q1 2018 | -5.0% | +5.3% | -13.3% | |
| Q2 2018 | +0.0% | -2.1% | -3.5% | |
| Q4 2017 | +4.7% | +4.7% | -11.0% | |
| Q3 2017 | -2.0% | -2.0% | -20.6% | |
| Q2 2017 | -8.6% | -4.8% | -32.9% | |
| Q1 2017 | +7.4% | +0.0% | -19.3% | |
| Q3 2016 | -17.8% | — | — | |
| Q2 2016 | +2.7% | — | — | |
| Q1 2016 | -1.1% | — | — | |
| Q3 2015 | -2.5% | — | — | |
| Q2 2014 | +4.2% | — | — | |
| Q3 2014 | -4.6% | — | — | |
| Q1 2015 | +5.9% | — | — | |
| Q4 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro